Monopar Therapeutics Inc. MNPR
72.00 USD -0.68 (-0.94%)
At closeNov 13, 2026, 4:00 PM EST
72.00 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
67.70 Day range 73.48
50.07 52-week range 124.82
- YTD
- +10.26%
- 1 year
- -17.25%
News
benzinga.com Monopar Therapeutics Q3 EPS $(0.72) Beats $(0.80) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.80) by 10 percent. This is a 50 percent decrease over losses of…
globenewswire.com Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments…
globenewswire.com Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026 WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
benzinga.com This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.- benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
benzinga.com Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
- benzinga.com Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses…
benzinga.com HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.- benzinga.com Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections.…
benzinga.com Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
benzinga.com Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026. Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
benzinga.com Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced- benzinga.com Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses…
- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.- benzinga.com Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115 Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $115.
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026 
benzinga.com This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123 Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers the price target from $142 to $123.
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.
- benzinga.com Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses…
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100 Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.
- benzinga.com Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115 Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $115.
benzinga.com This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125 Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $125.
- benzinga.com Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142 Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price target from $80 to $142.
- benzinga.com Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115 Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price target from $77 to $115.
- benzinga.com HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $70 to $105.
- benzinga.com Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95 Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target from $76 to $95.
benzinga.com CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 to $104.
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85 Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $60 to $85.
- benzinga.com Lake Street Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $106 Lake Street initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $106.
benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $60 Price Target Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $60 price target.- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $87 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $87 price target.
- benzinga.com Monopar To Present 6-Year Data Showing Sustained Neurological Improvement With ALXN1840 in Wilson Disease On UWDRS Part II and III At ANA Annual Meeting Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease…
- benzinga.com BTIG Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $87 BTIG analyst Jeet Mukherjee initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $87.
- benzinga.com Raymond James Initiates Coverage On Monopar Therapeutics with Strong Buy Rating, Announces Price Target of $80 Raymond James analyst Chris Raymond initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy rating and announces Price Target of $80.
- benzinga.com Oppenheimer Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $77 Oppenheimer analyst Andreas Argyrides initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $77.
- benzinga.com Cantor Fitzgerald Reiterates Overweight on Monopar Therapeutics, Maintains $74 Price Target Cantor Fitzgerald analyst Kristen Kluska reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and maintains $74 price target.
- benzinga.com HC Wainwright & Co. Assumes Monopar Therapeutics at Buy, Announces Price Target of $70 HC Wainwright & Co. analyst Andres Y. Maldonado assumes Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $70.
- benzinga.com Monopar Therapeutics Q2 EPS $(0.35) Beats $(0.49) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.49) by 28.57 percent. This is a 28.57 percent increase over losses…
- benzinga.com Cantor Fitzgerald Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $74 Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $74.
benzinga.com This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday